Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome

Basit Öğe Kaydı
dc.authoridMutlu, Kayhan/0000-0001-7447-2551
dc.authorwosiddikci, seyhan/A-3311-2019
dc.authorwosidYilmaz, Turgut/S-1198-2017
dc.contributor.authorYilmaz, Turgut
dc.contributor.authorDikci, Seyhan
dc.contributor.authorGenc, Oguzhan
dc.contributor.authorMutlu, Kayhan
dc.date.accessioned2024-08-04T20:09:51Z
dc.date.available2024-08-04T20:09:51Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPresumed ocular histoplasmosis syndrome (POHS) is a clinical entity that is characterized by small, round, discrete, macular or mid peripheral atrophic (punched out) chorioretinal lesions (histo spots), peripapillary scarring, choroidal neovascularization (CNV), and the absence of anterior uveitis and vitritis. Diagnosis of this disorder is based upon characteristic clinical findings and a positive histoplasmin skin test or residence in an endemic region for Histoplasma capsulatum. There is no active systemic disease during diagnosis of POHS. Disciform scarring and macular CNV secondary to POHS is a well-known complication which leads to loss of visual acuity or visual disturbance. Without therapy, the visual prognosis in these patients is unfavorable. Submacular surgery, radiation, steroids, photodynamic therapy, and most recently anti-vascular endothelial growth factor therapy are current therapeutic options for this condition. We report a case with persistent CNV secondary to POHS in a middle-aged woman with moderate myopia and the clinical course of treatment with multiple intravitreal ranibizumab (Lucentis (R), Novartis) injections.en_US
dc.identifier.doi10.4274/tjo.82956
dc.identifier.endpage118en_US
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.issue2en_US
dc.identifier.pmid28405488en_US
dc.identifier.scopus2-s2.0-85016415761en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage115en_US
dc.identifier.trdizinid288514en_US
dc.identifier.urihttps://doi.org/10.4274/tjo.82956
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/288514
dc.identifier.urihttps://hdl.handle.net/11616/92474
dc.identifier.volume47en_US
dc.identifier.wosWOS:000397191000012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Ophthalmological Socen_US
dc.relation.ispartofTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChoroidal neovascularizationen_US
dc.subjecthistoplasmosisen_US
dc.subjectintravitreal injectionen_US
dc.subjectranibizumaben_US
dc.titleMultiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu